Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Preferred Shares: 2014-2015

Historic Preferred Shares for Lineage Cell Therapeutics (LCTX) over the last 1 years, with Jun 2015 value amounting to $3.5 million.

  • Lineage Cell Therapeutics' Preferred Shares changed negligibly% to $3.5 million in Q2 2015 from the same period last year, while for Jun 2015 it was $3.5 million, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $3.5 million for FY2014, which is N/A change from last year.
  • Lineage Cell Therapeutics' Preferred Shares amounted to $3.5 million in Q2 2015, which was down 0.00% from $3.5 million recorded in Q1 2015.
  • In the past 5 years, Lineage Cell Therapeutics' Preferred Shares ranged from a high of $3.5 million in Q1 2014 and a low of $3.5 million during Q1 2014.
  • Moreover, its 2-year median value for Preferred Shares was $3.5 million (2015), whereas its average is $3.5 million.